PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PD PagerDuty, Inc.

已收盘 11-06 16:00:00 EST

15.68

-0.55

-3.39%

盘后15.82

+0.14+0.89%

19:30 EST

最高16.29	最低15.65	成交量104.71万
今开16.10	昨收16.23	日振幅3.94%
总市值12.33亿	流通市值11.08亿	总股本7,865万
成交额1,657万	换手率1.48%	流通股本7,064万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":15.68,"timestamp":1793998800000,"preClose":16.23,"halted":0,"volume":1047093,"hourTrading":{"tag":"盘后","latestPrice":15.82,"preClose":15.68,"latestTime":"19:30 EST","volume":33643,"amount":527709.07,"timestamp":1794011405035,"change":0.14,"changeRate":0.008929,"amplitude":0.009566},"delay":0,"changeRate":-0.033887861983980326,"floatShares":70635553,"shares":78649873,"eps":2.03,"marketStatus":"已收盘","change":-0.55,"latestTime":"11-06 16:00:00 EST","open":16.1,"high":16.29,"low":15.65,"amount":16572449.808672,"amplitude":0.039433,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.03,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1794214800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1554955200000,"exchange":"NYSE","adjPreClose":16.23,"preHourTrading":{"tag":"盘前","latestPrice":16.2196,"preClose":16.23,"latestTime":"09:16 EST","volume":1543,"amount":25171.387954,"timestamp":1793974589844,"change":-0.0104,"changeRate":-0.000641,"amplitude":0.165126},"postHourTrading":{"tag":"盘后","latestPrice":15.82,"preClose":15.68,"latestTime":"19:30 EST","volume":33643,"amount":527709.07,"timestamp":1794011405035,"change":0.14,"changeRate":0.008929,"amplitude":0.009566},"volumeRatio":0.779428,"impliedVol":0.7003,"impliedVolPercentile":0.3944},"requestUrl":"/m/hq/s/PD","defaultTab":"news","newsList":[{"id":"2679763294","title":"国产GPU从“能用”走向高价值竞争：比拼有效算力与商业化能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2679763294","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679763294?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:05","pubTimestamp":1793264735,"startTime":"0","endTime":"0","summary":"国产GPU的竞争，正在从性能追赶转向应用价值比拼。10月28日，国产GPU企业天数智芯（09903.HK）举办2026媒体开放日活动，首次面向媒体开放天垓300实机演示。公司披露的第三方实测结果显示，在典型的Prefill与Decode（PD）分离部署条件下，天垓300折算单卡整体端到端吞吐达到英伟达H200的1.05倍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610293914280477.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610293914280477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["WISE","BK4588","FTXL","SMH","SOXS","PSI","BK4023","CHAT","PD","SOXL","SOXQ","BK4585","SOXX","SOXY","LU1169590202.USD","LU1169589451.USD","CHPY","09903","CHPS","BK4535","SMHU","VGT","BK1163","SMHX","USD","TEKX","SSG","XSD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678155729","title":"趋境科技获13亿元B轮融资 “高质Token”的吸引力靠谱吗","url":"https://stock-news.laohu8.com/highlight/detail?id=2678155729","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678155729?lang=zh_cn&edition=full","pubTime":"2026-10-26 11:56","pubTimestamp":1792987001,"startTime":"0","endTime":"0","summary":"近日，高品质 AI Token 生产服务商趋境科技（Approaching.AI）完成 B 轮融资，...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3784449","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTHR","CHAT","BK4023","LU1169589451.USD","PD","AGIX","QTOC","LU1169590202.USD","AIPO","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667697972","title":"港股异动 | 维立志博-B(09887)高开近3% PD-L1/4-1BB双抗一线NSCLC缓解率与PFS率实现双重突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2667697972","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667697972?lang=zh_cn&edition=full","pubTime":"2026-09-15 09:30","pubTimestamp":1789435810,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B高开近3%，截至发稿，涨2.44%，报63港元，成交额458.64万港元。消息面上，9月14日，维立志博-B发布公告，在2026年世界肺癌大会以口头报告形式发布自主研发的在研药物维利信联合化疗一线治疗非小细胞肺癌患者的II期临床研究更新资料。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PD","LU1169589451.USD","BK4588","BK4023","HK0000500386.USD","KCAI","LU1169590202.USD","VXUS","HK0000252160.HKD","HK0000252152.HKD","BK1161","BK4585","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654690","title":"维立志博-B(09887)：在WCLC 2026以口头报告形式发布维利信®(奥帕替苏米单抗，PD-L1/4-1BB双抗)联合化疗一线治疗NSCLC的II期临床研究更新资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654690","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667654690?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:20","pubTimestamp":1789377635,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，在2026年世界肺癌大会以口头报告形式发布自主研发的在研药物维利信联合化疗一线治疗非小细胞肺癌患者的II期临床研究更新资料。非鳞状NSCLC PD-L1阳性亚组ORR达81.8%，DCR达100.0%，6个月PFS率达90.0%。维利信联合化疗整体安全性良好，安全性特征与PD-L1单抗联合化疗相似，未观察到新的安全信号。目前，本公司正在积极推进维利信一线治疗NSCLC的III期临床研究布局，力争早日让这款创新疗法惠及更多患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PD","LU1169589451.USD","BK4023","HK0000500386.USD","LU1169590202.USD","HK0000252160.HKD","HK0000252152.HKD","BK1161","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664842856","title":"康方生物(09926.HK)：依沃西对比帕博利珠用于一线治疗PD -L1表达阳性NSCLC的HARMONi-2研究期中分析达到OS关键次要终点 具有统计学显著和临床获益","url":"https://stock-news.laohu8.com/highlight/detail?id=2664842856","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664842856?lang=zh_cn&edition=full","pubTime":"2026-09-03 07:11","pubTimestamp":1788390684,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4023","PD","LU1169589451.USD","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178051887","title":"PagerDuty宣布裁员约15%——SEC文件披露重组细节","url":"https://stock-news.laohu8.com/highlight/detail?id=1178051887","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178051887?lang=zh_cn&edition=full","pubTime":"2026-08-28 04:48","pubTimestamp":1787863709,"startTime":"0","endTime":"0","summary":"8月27日（路透社）——PagerDuty, Inc.今日向美国证券交易委员会提交的文件中宣布，公司将进行约15%的员工人数削减。根据文件内容，PagerDuty预计此次裁员将产生550万美元至750万美元的非经常性费用。通过精简组织结构，PagerDuty旨在提升运营效率并重新聚焦核心业务领域。文件同时指出，此次重组涉及的具体部门及员工影响范围尚未完全披露，但公司承诺将按相关法规要求履行对受影响员工的责任和义务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","PD","LU1169590202.USD","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162660383","title":"PagerDuty预计裁员相关非经常性费用在550万至750万美元之间——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1162660383","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162660383?lang=zh_cn&edition=full","pubTime":"2026-08-28 04:08","pubTimestamp":1787861293,"startTime":"0","endTime":"0","summary":"PagerDuty, Inc.在最新提交的SEC文件中透露，公司预计与裁员计划相关的非经常性费用将在550万至750万美元区间内。值得注意的是，这一费用预估反映了PagerDuty在优化运营效率方面的积极举措，同时也暗示了公司正面临需要重新配置资源的经营环境。具体的费用构成和裁员规模等详细情况，在该SEC文件中均有进一步说明。PagerDuty作为一家提供数字运营管理平台的技术公司，其人员调整决策往往被视为行业风向标之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","PD","LU1169590202.USD","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119927725","title":"PagerDuty披露重组计划：2027财年第三季度计提重组费用，第四季度末完成裁员","url":"https://stock-news.laohu8.com/highlight/detail?id=1119927725","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119927725?lang=zh_cn&edition=full","pubTime":"2026-08-28 04:08","pubTimestamp":1787861291,"startTime":"0","endTime":"0","summary":"PagerDuty, Inc.向美国证券交易委员会提交的文件显示，该公司预计将在2027财年第三季度确认重组相关费用，并计划于2027财年第四季度末完成人员精简工作。与此同时，PagerDuty的裁员计划也有明确时间表——所有涉及的人员缩减将在2027财年第四季度末前画上句号。这一举措表明公司正积极重塑组织架构，以应对当前市场环境下的业务需求。此次重组计划的细节通过官方SEC文件对外公布，为投资者和市场观察者提供了关于公司未来走向的明确信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","BK4023","LU1169590202.USD","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662105790","title":"惠正奇医药创始人回爱民：mRNA癌症疫苗大规模应用仍需3-5年，不会取代CAR-T或PD-1/PD-L1疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2662105790","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662105790?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:30","pubTimestamp":1787740212,"startTime":"0","endTime":"0","summary":"如果后续获得监管批准，它将成为全球首个上市的mRNA肿瘤疫苗，开启个体化肿瘤疫苗治疗的新时代。回爱民：我认为，mRNA个性化癌症疫苗不会简单取代CAR-T或PD-1/PD-L1疗法，而是会带来差异化竞争和新的联合模式。因此，mRNA疫苗对PD-1/PD-L1疗法的影响主要是协同增效。intismeran取得阳性结果的方案本身就是与帕博利珠单抗联合，说明个性化疫苗未来更可能扩大PD-1/PD-L1疗法的获益人群，而不是取代它。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787738561624097620","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1574","LU1169589451.USD","BK4022","09939","CAR","BK4023","BK1161","BK4230","159938","PD","LU1169590202.USD","159646","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662192769","title":"挑战PD-L1“药王”成功，康方生物的PD-1双抗擂台赛从肺癌打到了胆道癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2662192769","media":"第一财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662192769?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:33","pubTimestamp":1787708009,"startTime":"0","endTime":"0","summary":"继头对头挑战默沙东K药物后，康方生物（09926.HK)的PD-1/VEGF双抗依沃西擂台赛还在继续。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608263854239539.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608263854239539.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0417516738.SGD","BK1574","LU0561508036.HKD","BK4023","LU0348766576.USD","LU0540923850.HKD","LU1169589451.USD","IE00BPRC5H50.USD","BK1161","LU0348827113.USD","LU0348783233.USD","LU2476274308.USD","IE00B543WZ88.USD","LU0348784397.USD","LU0348735423.USD","LU0417516902.SGD","LU0348825331.USD","LU1169590202.USD","09926","LU2778985437.USD","LU0348767384.USD","LU1720050803.USD","PD","LU1961090484.USD","LU1794554557.SGD","LU0417516571.SGD","LU2488822045.USD","LU2399975544.HKD","LU0634319403.HKD","IE00B5MMRT66.SGD","KURE","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662020178","title":"维立志博-B(09887)：维利信®(奥帕替苏米单抗，PD-L1/4-1BB双特异性抗体，LBL-024)一线治疗ESCC的Ⅱ期临床研究进入扩展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2662020178","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662020178?lang=zh_cn&edition=full","pubTime":"2026-08-25 06:56","pubTimestamp":1787612198,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，本公司自主研发的在研药物维利信一线治疗局部晚期或转移性食管鳞癌的Ⅱ期临床研究，已完成安全性导入期并在观察到的积极疗效信号及良好的安全性和耐受性基础上，顺利进入扩展阶段。截至目前，维利信一线治疗肺外神经内分泌癌、小细胞肺癌及胆道癌的三项POC研究已全部完成患者入组，其中一线EP-NEC已进入确证性III期临床阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169589451.USD","LU1169590202.USD","PD","BK4023","HK0000252152.HKD","HK0000252160.HKD","09887","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658970199","title":"康方生物(09926)：依达方®(依沃西，PD-1/VEGF)第三个适应症上市申请获得国家药品监督管理局批准，用于一线治疗SQ-NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2658970199","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658970199?lang=zh_cn&edition=full","pubTime":"2026-08-12 21:01","pubTimestamp":1786539717,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物 发布公告，由公司自主研发的全球首创双特异性抗体依达方联合化疗用于一线治疗晚期鳞状非小细胞肺癌的新药上市申请，已获得中国国家药品监督管理局批准上市。这是依沃西获批上市的第三个适应症。依沃西联合化疗一线治疗sq-NSCLC新适应症的获批上市，是基于依沃西联合化疗对比替雷利珠单抗联合化疗一线治疗晚期sq-NSCLC的随机、对照、多中心III期临床研究中获得的显著阳性结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348766576.USD","09926","LU2476274308.USD","LU1169589451.USD","LU0348783233.USD","LU0417516738.SGD","LU0348825331.USD","LU2778985437.USD","LU0634319403.HKD","LU1720050803.USD","LU0348827113.USD","LU2476274720.SGD","BK1574","IE00BPRC5H50.USD","KURE","LU0540923850.HKD","LU1169590202.USD","LU1961090484.USD","IE00B543WZ88.USD","LU2488822045.USD","IE00B5MMRT66.SGD","LU0417516571.SGD","PD","LU2399975544.HKD","LU0348784397.USD","IPOS","BK1161","LU0348767384.USD","LU0417516902.SGD","LU0561508036.HKD","BK4023","LU0348735423.USD","LU1794554557.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657904156","title":"把肿瘤变成“原位疫苗”!Replimune(REPL.US)溶瘤病毒闯过FDA，PD-1耐药黑色素瘤迎来新一代免疫重启方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2657904156","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657904156?lang=zh_cn&edition=full","pubTime":"2026-08-07 14:59","pubTimestamp":1786085956,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PD","BK4585","BK4588","BK4139","BK4023","LU1169589451.USD","LU1169590202.USD","REPL","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655490356","title":"复宏汉霖(02696)：注射用HLX43(靶向PD-L1抗体偶联药物)联合贝伐珠单抗联合或不联合化疗用于晚期/转移性实体瘤治疗的临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655490356","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655490356?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:33","pubTimestamp":1785486809,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，注射用HLX43联合贝伐珠单抗联合或不联合化疗用于晚期/转移性实体瘤治疗的临床试验申请获国家药品监督管理局批准。HLX43是由本公司利用许可引进的新型DNA拓扑异构酶I抑制剂小分子毒素-肽链连接子与本公司自主研发的靶向PD-L1的抗体进行偶联开发的靶向PD-L1的抗体偶联药物，拟用于晚期/转移性实体瘤的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","IBBJ","HK0000306701.USD","IBBQ","02696","HK0000320223.HKD","PD","HK0000165453.HKD","MDTX","PSYK","HK0000320264.USD","BMED","BK1161","LU1169590202.USD","HK0000306685.HKD","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652298475","title":"无问芯穹夏立雪：随着跨集群异构PD分离架构规模化落地，推理成本仍有10倍下降空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2652298475","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652298475?lang=zh_cn&edition=full","pubTime":"2026-07-20 15:21","pubTimestamp":1784532097,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PD","LU1169589451.USD","BK4023","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652638792","title":"基石药业-B(02616)：ESMO 2026预告-更多临床数据进一步验证 CS2009(PD-1/VEGF/CTLA-4三特异性抗体)临床潜力与全球开发前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2652638792","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652638792?lang=zh_cn&edition=full","pubTime":"2026-07-20 08:06","pubTimestamp":1784505987,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B(02616)发布公告，公司核心资产之一CS2009(PD-1/VEGF/CTLA-4三特异性抗体)的临床研究成果成功入选2026年欧洲肿瘤内科学会(ESMO)年会，并将以两项快速口头报告的形式呈现，分别涵盖CS2009在晚期非小细胞肺癌(NSCLC)以及转移性结直肠癌(mCRC)患者中的I/II期临床试验数据。目前，相关摘要标题已在ESMO官网公布。需说明的是，摘要中所呈现的数据仅截至2026年4月，旨在符合大会递交期限之要求。基石药业将于2026年10月23日至26日在西班牙马德里召开的ESMO年会现场，展示数据截止日期更临近会议时间的临床研究结果。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","LU1169589451.USD","BK1574","BK4023","BK1161","LU1169590202.USD","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651348206","title":"科伦博泰生物(06990)：核心产品TROP2ADC芦康沙妥珠单抗(sac-TMT)联合帕博利珠单抗一线治疗PD-L1阴性局部晚期或转移性非鳞状非小细胞肺癌3期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651348206","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651348206?lang=zh_cn&edition=full","pubTime":"2026-07-15 07:32","pubTimestamp":1784071939,"startTime":"0","endTime":"0","summary":"安全性方面，芦康沙妥珠单抗联合帕博利珠单抗的安全性特征与既往研究报告一致，未观察到新的安全性信号。目前，本公司已在中国开展9项注册性临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169590202.USD","LU0196878994.USD","06990","PD","BK1161","LU1169589451.USD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651104260","title":"安捷伦PD-L1伴随诊断试剂获FDA批准，用于食管胃癌免疫治疗筛选","url":"https://stock-news.laohu8.com/highlight/detail?id=2651104260","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651104260?lang=zh_cn&edition=full","pubTime":"2026-07-14 22:38","pubTimestamp":1784039880,"startTime":"0","endTime":"0","summary":"安捷伦科技公司近日宣布，其PD-L1 IHC 28-8 pharmDx试剂盒已获得美国食品药品监督管理局的批准，可作为伴随诊断工具，用于识别可能适合接受免疫治疗的患者。该试剂盒现可正式用于评估食管鳞状细胞癌、胃癌、胃食管交界处癌及食管腺癌患者的PD-L1蛋白表达水平。　　安捷伦表示，此次获批有助于标准化相关癌症的免疫治疗患者筛选流程，支持全球临床医生做出更精准的治疗决策。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-14/doc-inihuxfu8357115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","LABU","LU1169590202.USD","PD","LU1169589451.USD","BK4023","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650907155","title":"恒瑞医药回应PD-1联合疗法在美延迟批准：未涉及产品临床研究数据问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2650907155","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650907155?lang=zh_cn&edition=full","pubTime":"2026-07-10 14:43","pubTimestamp":1783665784,"startTime":"0","endTime":"0","summary":"恒瑞医药回应PD-1联合疗法在美延迟批准：未涉及产品临床研究数据问题","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607103801735795.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607103801735795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4023","BK0239","BK0183","LU2495084118.USD","LU1781817850.SGD","LU2488822045.USD","LU2148510915.USD","LU0359201885.HKD","LU2097828474.EUR","LU1969619763.USD","LU1023057109.AUD","LU2289578879.USD","LU1655091616.SGD","BK0060","LU1997245094.SGD","LU1146622755.USD","LU2580892862.HKD","LU2097828557.USD","LU2543165471.USD","PD","LU2097828805.USD","LU0405327494.USD","LU1580142542.USD","LU1820825898.SGD","BK0012","LU0405327148.USD","LU1064131003.USD","LU2328871848.SGD","LU2580892789.USD","LU1064130708.USD","600276","LU0359202008.SGD","LU2097828714.EUR","LU1328615791.USD","LU1997244956.HKD","BK0196","LU1997245177.USD","LU2097828631.EUR","BK0028","BK1191","LU0359201612.USD","BK0188","01276","LU1169590202.USD","LU1255011170.USD","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648220025","title":"和誉-B(02256)附属与阿斯利康达成战略合作开展同类首创口服PD-L1抑制剂ABSK043联合泰瑞沙®治疗非小细胞肺癌的临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2648220025","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648220025?lang=zh_cn&edition=full","pubTime":"2026-07-02 08:06","pubTimestamp":1782950774,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，本公司的附属公司上海和誉生物医药科技有限公司宣布，与阿斯利康签署战略合作协议，共同推进一项新型靶免联合疗法治疗非小细胞肺癌的临床研究。该联合研究是一项多中心、开放的I/II期临床试验，旨在评估和誉医药自主研发的同类首创口服小分子PD-L1抑制剂 ABSK043联合阿斯利康第三代EGFR-TKI泰瑞沙 ，用于治疗EGFR突变合并PD-L1阳性的局部晚期或转移性NSCLC患者中的安全性和疗效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","LU2462157665.USD","BK4585","LU2237443465.HKD","02256","BK4588","LU0310800379.SGD","IE00B543WZ88.USD","LU1169589451.USD","LU2778985437.USD","LU0109394709.USD","LU0058720904.USD","BK4568","LU2237443549.SGD","LU2417539215.USD","LU0029864427.USD","LU0320765992.SGD","LU0128525929.USD","IE00B3T34201.USD","AZN","BK4007","LU2468319806.SGD","LU0889565916.HKD","AZNH","LU2237443382.USD","LU2089984988.USD","LU2476274308.USD","LU2488822045.USD","LU2476274720.SGD","LU0708994859.HKD","LU2237443978.SGD","LU2456880835.USD","IE00BPRC5H50.USD","LU1267930573.SGD","LU0432979614.USD","LU1829250122.USD","LU1169590202.USD","LU2236285917.USD","LU2237443622.USD","PD","LU2237443895.HKD","LU0289739699.SGD","BK1161","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pagerduty.com","stockEarnings":[{"period":"1week","weight":-0.0662},{"period":"1month","weight":0.0512},{"period":"3month","weight":0.3884},{"period":"6month","weight":1.2263},{"period":"1year","weight":0.0594},{"period":"ytd","weight":0.238}],"compareEarnings":[{"period":"1week","weight":-0.0473},{"period":"1month","weight":-0.0592},{"period":"3month","weight":-0.0521},{"period":"6month","weight":-0.0063},{"period":"1year","weight":0.0818},{"period":"ytd","weight":0.0749}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"PagerDuty, Inc.于2010年5月根据特拉华州法律成立。该公司及其全资子公司提供了一个数字运营管理平台，为现代数字业务管理紧急和关键任务工作（“PagerDuty平台”）。PagerDuty平台从几乎任何支持软件的系统或设备收集数据和数字信号，并利用先进的人工智能和强大的机器学习实时关联、处理、预测和补救事件和机会。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.011871},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.075547},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.032883},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.032585},{"month":5,"riseRate":0.375,"avgChangeRate":0.055631},{"month":6,"riseRate":0.625,"avgChangeRate":0.015298},{"month":7,"riseRate":0.625,"avgChangeRate":0.027655},{"month":8,"riseRate":0.625,"avgChangeRate":0.041604},{"month":9,"riseRate":0.125,"avgChangeRate":-0.091435},{"month":10,"riseRate":0.375,"avgChangeRate":-0.016638},{"month":11,"riseRate":0.5,"avgChangeRate":0.013279},{"month":12,"riseRate":0.571429,"avgChangeRate":0.042574}],"exchange":"NYSE","name":"PagerDuty, Inc.","nameEN":"PagerDuty, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PagerDuty, Inc.,PD,PagerDuty, Inc.股票,PagerDuty, Inc.股票老虎,PagerDuty, Inc.股票老虎国际,PagerDuty, Inc.行情,PagerDuty, Inc.股票行情,PagerDuty, Inc.股价,PagerDuty, Inc.股市,PagerDuty, Inc.股票价格,PagerDuty, Inc.股票交易,PagerDuty, Inc.股票购买,PagerDuty, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}